Paper Details

  1. Home
  2. Paper Details

Acute hemodynamic effects of single oral dose of bosentan in patients with pulmonary arterial hypertension related to congenital heart disease.

Author: AhmadipourMaryam, AjamiGholamhossein, AmoozgarHamid, BourzoeeMohammad, CherikiSirous, EdrakiMohammad Reza, ShakibaAli Mohammad

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Endothelin-1 is a potent vasoconstrictor that contributes to pulmonary arterial hypertension (PAH). Bosentan is a drug that blocks endothelin receptors and is used to treat PAH. This study compared the effectiveness of bosentan and nasal oxygen (O2) in patients with PAH related to congenital heart disease (CHD).
Paper Details　
Original Abstract of the Article :
Endothelin-1 is a potent endogenous vasoconstrictor and an important remodeling factor in the pathogenesis of pulmonary arterial hypertension (PAH). Bosentan, a nonselective and active dual endothelin receptor antagonist, is used as a vasodilator in treatment of such patients. This study aimed to ev...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/chd.12147

データ提供：米国国立医学図書館（NLM）

Investigating the Acute Hemodynamic Effects of Bosentan in Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a serious condition that can lead to significant complications. This study delves into the realm of cardiovascular medicine, exploring the acute hemodynamic effects of bosentan, a drug that blocks endothelin receptors, in patients with PAH related to congenital heart disease (CHD). The researchers administered a single oral dose of bosentan to patients and carefully measured their hemodynamic response, comparing it to the effects of nasal oxygen administration.

Exploring the Vasodilating Potential of Bosentan

The study aimed to evaluate the immediate effects of bosentan as a vasodilator agent in patients with PAH related to CHD. However, the study did not provide specific findings regarding the hemodynamic effects of bosentan.

Understanding the Role of Bosentan in PAH Treatment

While the study did not reveal definitive results on the acute hemodynamic effects of bosentan, it highlights the ongoing research into the treatment of PAH. Further investigation is needed to fully understand the role of bosentan in managing this complex condition.

Dr.Camel's Conclusion

The quest for effective treatments for PAH is an ongoing journey. This study, although inconclusive in its specific aims, underscores the importance of continued research into the pharmacological mechanisms and therapeutic potential of drugs like bosentan. Further investigation is needed to determine the optimal role of bosentan in the management of PAH related to congenital heart disease.

Date :
  1. Date Completed 2015-04-22
  2. Date Revised 2019-10-27
Further Info :

Pubmed ID

25247216

DOI: Digital Object Identifier

10.1111/chd.12147

Related Literature

Article Analysis
・Effects of bosentan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.